Mode
Text Size
Log in / Sign up
Phase 3 N=117 Randomized Single-blind Treatment

Treatment of Encopresis in Children With Autism Spectrum Disorders

Encopresis · Autism Spectrum Disorder

Enrolled (actual)
117
Serious AEs
0.0%
Results posted
Jan 2024
Primary outcome: Primary: Percentage of Continent Bowel Movements — 27.33; 16.99; 20.70; 55.50 percentage of bowel movements

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
MIE Treatment (Behavioral); Glycerin Suppository (Drug); Treatment as Usual (TAU) (Combination_product)
Age
Pediatric · 5+ yrs
Sex
All
Sponsor
Emory University
Primary completion
Nov 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Continent Bowel Movements
27.33; 16.99; 20.70; 55.50; 79.69; 37.74
SECONDARY
Number of Children Responding to Treatment as Rated by the Clinical Global Impression Scale - Improvement (CGI-I) Score
16; 26; 37; 10; 21; 7
SECONDARY
Parenting Stress Index Short Form Total Score
82.38; 81.72; 91.22; 80.88; 82.76; 89.19
SECONDARY
Caregiver Strain Questionnaire - Short Form 7 (CGSQ-SF7) Objective Strain Subscale Score
9.68; 9.86; 9.40; 9.53; 8.21; 9.29
SECONDARY
Caregiver Strain Questionnaire - Short Form 7 (CGSQ-SF7) Subjective Internalized Strain Subscale Score
8.88; 10.16; 9.29; 9.06; 7.24; 9.58
SECONDARY
Caregiver Strain Questionnaire - Short Form (CGSQ-SF7) Total Score
18.56; 20.03; 18.69; 18.59; 15.45; 18.87

Summary

This study is comparing a multidisciplinary intervention for encopresis (MIE), consisting of both medical and behavioral components to treatment as usual control (TAU). Participants are first screened by a pediatric gastroenterologist and assessed and treated for any constipation or other potential medical complications. Following this, caregivers collect data on bowel movements and continence during a home baseline lasting no less than 14 days and no more than 21 days. Participants randomly assigned to treatment as usual or the treatment group, and begin attending daily appointments in clinic for 2 weeks. At appointments, the behavior team implements structured sits on the toilet to promote independent bowel movements (BMs). If an independent BM does not occur, the study team will administer a suppository to promote rapid release of the bowels and prompt the child to remain on the toilet following administration. In doing so, continent bowel movements are predictably evoked while the child is on the toilet, allowing for reinforcement with praise and preferred toys/activities. Eventually, suppositories are gradually decreased until the child is having BMs independently. Caregivers are trained to continue implementing the intervention following the clinic-based portion. The purpose of the current study is to evaluate MIE using a large randomized clinical trial (RCT), addressing the Department of Defense Autism Research Program, Area of Interest of Therapies to Alleviate Conditions Co-Occurring with autism spectrum disorder (ASD). The researchers will recruit 112 children diagnosed with ASD, randomizing them to two weeks of MIE, or treatment as usual (TAU) consisting of behavioral consultation and medical intervention. This study will evaluate MIE compared to TAU and determine the optimal treatment length.

Eligibility Criteria

Inclusion Criteria

  • Males and females from 5 years of age to 12 years 11 months of age.
  • Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnosis of Autism Spectrum Disorder as established by clinical assessment, corroborated by the Autism Diagnostic Observational Schedule, Autism Diagnostic Interview-Revised and/or Childhood Autism Rating Scale-Second Edition.
  • Fewer than 60% of days are continent days or more than 1 day out of 7 is an incontinent day over the previous 7 days (a continent day is defined as a day with at least one continent bowel movement. An incontinent day is a day with an incontinent bowel movement regardless of whether a continent bowel movement also occurs).
  • Medication free or on stable medication (no changes in past 6 weeks and no planned changes for the next 6 months).
  • Urine continent - Over half of the voids are continent when the child is with the parent and when the child is on a typical toileting routine.

Exclusion Criteria

  • Presence of a known medical condition in the child (based on medical history or physical examination) that would interfere with child's ability to control his/her anus. These include: history of any anal surgery, spinal dysraphism (e.g., spina bifida), other neurologic disorder affecting anal function, and prolonged/recurrent gastrointestinal infectious disease (e.g. Clostridium difficile colitis). In addition, the following may constitute exclusions following evaluation by a physician: inflammatory bowel disease, short gut syndrome, chronic diarrhea, or history of intestinal/abdominal surgery.
  • Presence of a current serious behavioral problem or psychiatric condition that would require another treatment (e.g., psychotic disorder, major depression, moderate or greater aggression, severe disruptive behavior), based on information collected at screening and the Behavior Problems Inventory-01 (BPI-01).
  • Currently receiving and caregiver refusal to discontinue ongoing behavioral or alternative medical intervention for encopresis.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03197922). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search